Why Is AT&T Stock Dropping?
The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…
Buy
58
QGEN Quote, Financials, Valuation and Earnings
Last price:
$46.01
Seasonality move
:
2.29%
Day range:
$45.77 - $46.36
52-week range:
$39.03 - $47.44
Dividend yield:
0%
P/E ratio:
113.12x
P/S ratio:
5.12x
P/B ratio:
2.90x
Volume:
1.2M
Avg. volume:
833.7K
1-year change:
-0.18%
Market cap:
$10.2B
Revenue:
$2B
EPS (TTM):
$0.41
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$481.1M | $0.49 | 4.87% | 34.32% | $51.14 |
|
HAE
Haemonetics
|
$359M | $1.29 | 5.26% | 92.62% | $110.80 |
|
LENZ
LENZ Therapeutics
|
-- | -$0.62 | -- | -57.13% | $39.29 |
|
MRUS
Merus NV
|
$9.2M | -$0.94 | -4.27% | -10.77% | $86.07 |
|
ORKA
Oruka Therapeutics
|
-- | -$0.31 | -- | -29.53% | $43.17 |
|
RMD
ResMed
|
$1.3B | $2.39 | 9.72% | 64.2% | $256.02 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$46.00 | $51.14 | $10.2B | 113.12x | $1.28 | 0% | 5.12x |
|
HAE
Haemonetics
|
$73.49 | $110.80 | $3.7B | 30.49x | $0.00 | 0% | 2.78x |
|
LENZ
LENZ Therapeutics
|
$22.50 | $39.29 | $618.8M | -- | $0.00 | 0% | -- |
|
MRUS
Merus NV
|
$39.45 | $86.07 | $2.7B | -- | $0.00 | 0% | 67.53x |
|
ORKA
Oruka Therapeutics
|
$12.25 | $43.17 | $428.7M | -- | $0.00 | 0% | -- |
|
RMD
ResMed
|
$239.78 | $256.02 | $35.2B | 31.76x | $0.53 | 0.84% | 7.36x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
QGEN
Qiagen NV
|
35.23% | 0.190 | 18.96% | 1.62x |
|
HAE
Haemonetics
|
58.23% | 0.862 | 30.25% | 1.87x |
|
LENZ
LENZ Therapeutics
|
-- | 3.796 | -- | -- |
|
MRUS
Merus NV
|
-- | 1.670 | -- | 7.94x |
|
ORKA
Oruka Therapeutics
|
-- | 0.000 | -- | -- |
|
RMD
ResMed
|
11.54% | -0.342 | 1.89% | 1.37x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
QGEN
Qiagen NV
|
$308.3M | $120.8M | 1.8% | 2.58% | 25.49% | $138M |
|
HAE
Haemonetics
|
$187.4M | $51.7M | 6.54% | 13.51% | 14.96% | $39.4M |
|
LENZ
LENZ Therapeutics
|
-- | -$12.9M | -- | -- | -- | -$10.8M |
|
MRUS
Merus NV
|
-- | -$72.2M | -47.97% | -47.97% | -613.59% | -$80.7M |
|
ORKA
Oruka Therapeutics
|
-- | -$29.4M | -- | -- | -- | -- |
|
RMD
ResMed
|
$717.2M | $387.3M | 19.59% | 23.76% | 31.63% | $305.9M |
Qiagen NV vs. Competitors
-
Which has Higher Returns QGEN or HAE?
Haemonetics has a net margin of 19.54% compared to Qiagen NV's net margin of 9.79%. Qiagen NV's return on equity of 2.58% beat Haemonetics's return on equity of 13.51%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B HAEHaemonetics54.25% $0.66 $2.1B -
What do Analysts Say About QGEN or HAE?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 11.18%. On the other hand Haemonetics has an analysts' consensus of $110.80 which suggests that it could grow by 50.77%. Given that Haemonetics has higher upside potential than Qiagen NV, analysts believe Haemonetics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 HAEHaemonetics3 2 0 -
Is QGEN or HAE More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison Haemonetics has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.02%.
-
Which is a Better Dividend Stock QGEN or HAE?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Haemonetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Haemonetics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or HAE?
Qiagen NV quarterly revenues are $501.9M, which are larger than Haemonetics quarterly revenues of $345.5M. Qiagen NV's net income of $98.1M is higher than Haemonetics's net income of $33.8M. Notably, Qiagen NV's price-to-earnings ratio is 113.12x while Haemonetics's PE ratio is 30.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.12x versus 2.78x for Haemonetics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.12x 113.12x $501.9M $98.1M HAEHaemonetics2.78x 30.49x $345.5M $33.8M
-
Which has Higher Returns QGEN or LENZ?
LENZ Therapeutics has a net margin of 19.54% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.58% beat LENZ Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B LENZLENZ Therapeutics-- -$0.38 -- -
What do Analysts Say About QGEN or LENZ?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 11.18%. On the other hand LENZ Therapeutics has an analysts' consensus of $39.29 which suggests that it could grow by 74.6%. Given that LENZ Therapeutics has higher upside potential than Qiagen NV, analysts believe LENZ Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 LENZLENZ Therapeutics4 0 0 -
Is QGEN or LENZ More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison LENZ Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or LENZ?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. LENZ Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. LENZ Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or LENZ?
Qiagen NV quarterly revenues are $501.9M, which are larger than LENZ Therapeutics quarterly revenues of --. Qiagen NV's net income of $98.1M is higher than LENZ Therapeutics's net income of -$10.2M. Notably, Qiagen NV's price-to-earnings ratio is 113.12x while LENZ Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.12x versus -- for LENZ Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.12x 113.12x $501.9M $98.1M LENZLENZ Therapeutics-- -- -- -$10.2M
-
Which has Higher Returns QGEN or MRUS?
Merus NV has a net margin of 19.54% compared to Qiagen NV's net margin of -848.67%. Qiagen NV's return on equity of 2.58% beat Merus NV's return on equity of -47.97%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B MRUSMerus NV-- -$1.46 $703.3M -
What do Analysts Say About QGEN or MRUS?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 11.18%. On the other hand Merus NV has an analysts' consensus of $86.07 which suggests that it could grow by 118.18%. Given that Merus NV has higher upside potential than Qiagen NV, analysts believe Merus NV is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 MRUSMerus NV12 0 0 -
Is QGEN or MRUS More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison Merus NV has a beta of 1.104, suggesting its more volatile than the S&P 500 by 10.426%.
-
Which is a Better Dividend Stock QGEN or MRUS?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Merus NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Merus NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or MRUS?
Qiagen NV quarterly revenues are $501.9M, which are larger than Merus NV quarterly revenues of $11.8M. Qiagen NV's net income of $98.1M is higher than Merus NV's net income of -$99.9M. Notably, Qiagen NV's price-to-earnings ratio is 113.12x while Merus NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.12x versus 67.53x for Merus NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.12x 113.12x $501.9M $98.1M MRUSMerus NV67.53x -- $11.8M -$99.9M
-
Which has Higher Returns QGEN or ORKA?
Oruka Therapeutics has a net margin of 19.54% compared to Qiagen NV's net margin of --. Qiagen NV's return on equity of 2.58% beat Oruka Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B ORKAOruka Therapeutics-- -$1.46 -- -
What do Analysts Say About QGEN or ORKA?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 11.18%. On the other hand Oruka Therapeutics has an analysts' consensus of $43.17 which suggests that it could grow by 252.38%. Given that Oruka Therapeutics has higher upside potential than Qiagen NV, analysts believe Oruka Therapeutics is more attractive than Qiagen NV.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 ORKAOruka Therapeutics6 0 0 -
Is QGEN or ORKA More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison Oruka Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock QGEN or ORKA?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. Oruka Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Qiagen NV pays -- of its earnings as a dividend. Oruka Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios QGEN or ORKA?
Qiagen NV quarterly revenues are $501.9M, which are larger than Oruka Therapeutics quarterly revenues of --. Qiagen NV's net income of $98.1M is higher than Oruka Therapeutics's net income of -$28.6M. Notably, Qiagen NV's price-to-earnings ratio is 113.12x while Oruka Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.12x versus -- for Oruka Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.12x 113.12x $501.9M $98.1M ORKAOruka Therapeutics-- -- -- -$28.6M
-
Which has Higher Returns QGEN or RMD?
ResMed has a net margin of 19.54% compared to Qiagen NV's net margin of 25.43%. Qiagen NV's return on equity of 2.58% beat ResMed's return on equity of 23.76%.
Company Gross Margin Earnings Per Share Invested Capital QGENQiagen NV61.43% $0.44 $5.4B RMDResMed58.57% $2.11 $5.9B -
What do Analysts Say About QGEN or RMD?
Qiagen NV has a consensus price target of $51.14, signalling upside risk potential of 11.18%. On the other hand ResMed has an analysts' consensus of $256.02 which suggests that it could grow by 6.77%. Given that Qiagen NV has higher upside potential than ResMed, analysts believe Qiagen NV is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings QGENQiagen NV7 7 0 RMDResMed6 8 1 -
Is QGEN or RMD More Risky?
Qiagen NV has a beta of 0.366, which suggesting that the stock is 63.358% less volatile than S&P 500. In comparison ResMed has a beta of 0.698, suggesting its less volatile than the S&P 500 by 30.155%.
-
Which is a Better Dividend Stock QGEN or RMD?
Qiagen NV has a quarterly dividend of $1.28 per share corresponding to a yield of 0%. ResMed offers a yield of 0.84% to investors and pays a quarterly dividend of $0.53 per share. Qiagen NV pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios QGEN or RMD?
Qiagen NV quarterly revenues are $501.9M, which are smaller than ResMed quarterly revenues of $1.2B. Qiagen NV's net income of $98.1M is lower than ResMed's net income of $311.4M. Notably, Qiagen NV's price-to-earnings ratio is 113.12x while ResMed's PE ratio is 31.76x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Qiagen NV is 5.12x versus 7.36x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income QGENQiagen NV5.12x 113.12x $501.9M $98.1M RMDResMed7.36x 31.76x $1.2B $311.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is American Express Stock Going Lower?
American Express Company (NYSE:AXP) has long been a Buffett favorite…
Cigna vs Costco Stock: Which Is Best?
Cigna and Costco don’t usually go hand in hand but…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 38x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
45
QMCO alert for Jan 18
Quantum [QMCO] is down 15.61% over the past day.
Buy
51
QRVO alert for Jan 18
Qorvo [QRVO] is up 14.47% over the past day.
Sell
31
ATEX alert for Jan 18
Anterix [ATEX] is up 11.14% over the past day.
